Alkermes Reports Mixed Results, Updates Guidance

Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While sales of key drugs Vivitrol and Aristada continue to grow rapidly, Alkermes' overall revenue growth came in much weaker than expected. As a result, management dialed back its revenue growth expectations for the full year. However, containment efforts helped the company to beat expectations on the bottom-line.

Data source: Alkermes. GAAP = generally accepted accounting principles.

Image source: Getty Images.

Source: Fool.com